Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Science Translational Medicine

Source Link:: http://ir.acorda.com/investors/investor-news/investor-news-details/2016/Data-from-Clinical-and-Preclinical-Trials-of-CVT-301-for-Treatment-of-OFF-Periods-in-Parkinsons-Disease-Published-in-Science-Translational-Medicine/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ACOR

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Results from Phase 1, Phase 2a and preclinical studies of CVT-301, an inhaled form of levodopa, have been featured in the current edition of Science Translational Medicine. Acorda Therapeutics, Inc. (NASDAQ:ACOR) is developing CVT-301 for the treatment of OFF periods in people with Parkinson’s disease (PD).

http://ir.acorda.com...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Oct 13, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Cvt-301, Parkinson’s Disease